58 completed, 11 terminated, 5 recruiting, 4 unknown. 85 Phase 3, 11 Phase 2.
Follow salicylhydroxamic acid: new trials by email Literature Review of salicylhydroxamic acid trials Research Report on salicylhydroxamic acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery Moxifloxacin, Placebo - Endophthalmitis | Phase 2 / Phase 3 | Not yet recruiting | Jason Ahee, M.D. | 60000 | 2027-06-01 | 2026-09-15 |
| Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema Surabgene Lomparvovec, Sham, Topical Steroid - Diabetic Retinopathy | Phase 2 / Phase 3 | Recruiting | AbbVie | 576 | 2026-06-01 | 2026-10-29 |
| A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension) - Postoperative Ocular Inflammation, Postoperative Ocular Pain | Phase 3 | Enrolling by invitation | Harrow Inc | 250 | 2026-05-25 | 2026-09-22 |
| A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease IDCT (rebonuputemcel), Sham (No Treatment) - Degenerative Disc Disease | Phase 3 | Recruiting | DiscGenics, Inc. | 162 | 2025-12-23 | 2026-10-15 |
| Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension Perirenal adipose tissue modification by focused power ultrasound, Sham - Resistant Hypertension | Phase 3 | Not yet recruiting | Yan Li | 220 | 2025-11-20 | 2025-11-18 |
| A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24 - Non-Proliferative Diabetic Retinopathy | Phase 3 | Recruiting | Ocular Therapeutix, Inc. | 930 | 2025-11-17 | 2026-03-16 |
| Bupivacaine and Epinephrine Injection Study Sensorcaine with Epinephrine, Sham injection - Sinus Disease, Anesthesia | Phase 2 / Phase 3 | Recruiting | Amin Javer | 80 | 2024-11-15 | 2025-05-15 |
| A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation rAAV2-ND4, Sham (No Treatment) - Leber Hereditary Optic Neuropathy (LHON) | Phase 3 | Active not recruiting | Wuhan Neurophth Biotechnology Limited Company | 95 | 2024-09-19 | 2026-02-12 |
| A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema 8 mg aflibercept (BAY 86-5321) (High Dose), 2 mg aflibercept (EYLEA, BAY 86-5321), Sham - Diabetic Macular Edema | Phase 3 | Completed | Bayer | 333 | 2024-05-29 | 2026-03-31 |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) Tarcocimab, Sham injection - Diabetic Retinopathy | Phase 3 | Completed | Kodiak Sciences Inc | 255 | 2024-05-01 | 2026-05-13 |
| Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy Intra-Arterial TNK and Albumin, Intra-Arterial TNK, Intra-Arterial Albumin - Acute Ischemic Stroke | Phase 3 | Unknown | Tianjin Huanhu Hospital | 80 | 2023-09-07 | 2023-11-02 |
| A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham - Macular Edema Secondary to Retinal Vein Occlusion | Phase 3 | Completed | Bayer | 892 | 2023-05-15 | 2026-06-17 |
| Vamikibart in Participants With Uveitic Macular Edema Vamikibart, Sham - Uveitic Macular Edema | Phase 3 | Completed | Hoffmann-La Roche | 256 | 2023-03-23 | 2026-04-17 |
| A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema Vamikibart, Sham - Uveitic Macular Edema | Phase 3 | Completed | Hoffmann-La Roche | 245 | 2023-01-09 | 2025-11-21 |
| The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Yutiq 0.18 MG Drug Implant, Sham Injection - Uveitis, Uveitis, Posterior | Phase 3 | Completed | Texas Retina Associates | 10 | 2022-10-05 | 2026-10-05 |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR) KSI-301, Sham injection - Non-proliferative Diabetic Retinopathy | Phase 3 | Terminated | Kodiak Sciences Inc | 253 | 2021-09-07 | 2024-09-05 |
| OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) 2.0 mg OPT-302, 2.0 aflibercept, Sham - Neovascular Age-related Macular Degeneration | Phase 3 | Terminated | Opthea Limited | 998 | 2021-03-12 | 2025-08-05 |
| OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) 2.0 mg OPT-302, 0.5 mg ranibizumab, Sham - Neovascular Age-related Macular Degeneration | Phase 3 | Terminated | Opthea Limited | 986 | 2021-03-12 | 2025-07-22 |
| A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) Avacincaptad Pegol, Sham - Geographic Atrophy, Macular Degeneration | Phase 3 | Completed | IVERIC bio, Inc. | 448 | 2020-06-22 | 2025-10-21 |
| Combined Ranibizumab and Iluvien for Diabetic Macular Oedema Iluvien 0.19 MG Drug Implant, Ranibizumab Injection [Lucentis], Sham Intravitreal Injection - Diabetic Macular Edema, Diabetes | Phase 2 / Phase 3 | Withdrawn | Imperial College London | 2019-09-01 | 2023-10-02 |
Showing 20 of 85. Sign in to see all of them.
Macular Edema (19) · Retinal Vein Occlusion (12) · Vision Disorders (11) · Macular Degeneration (8) · Retinal Diseases (6) · Diabetes Mellitus (5) · Diabetic Retinopathy (5) · Eye Diseases (5) · Choroidal Neovascularization (3) · Geographic Atrophy (3) · Optic Atrophy, Hereditary, Leber (3) · Retinal Degeneration (3) · Uveitis, Intermediate (3) · Uveitis, Posterior (3) · Bronchopulmonary Dysplasia (2)
Allergan (6) · Novartis Pharmaceuticals (6) · Genentech, Inc. (4) · Bayer (3) · Chengdu Kanghong Biotech Co., Ltd. (3) · Hoffmann-La Roche (3) · Ophthotech Corporation (3) · EyePoint Pharmaceuticals, Inc. (2) · IVERIC bio, Inc. (2) · Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA (2) · Jaeb Center for Health Research (2) · Kodiak Sciences Inc (2) · Opthea Limited (2) · Otonomy, Inc. (2) · Regeneron Pharmaceuticals (2)
United States (49) · Germany (21) · Canada (20) · United Kingdom (20) · France (18) · Israel (18) · China (17) · Italy (17) · Spain (17) · Czechia (15) · Australia (14) · Hungary (14) · Poland (14) · Brazil (12) · India (11)
Carl LeBel, PhD (2) · Jason Ehrlich, M.D., Ph.D. (2) · Pablo Velazquez-Martin, MD (2) · Roberta A Ballard, MD (2) · Roman Rubio, M.D. (2) · Alexander J. Brucker, M.D. (1) · Allen Hu, MD (1) · Amish Raval, MD (1) · Andrew N. Redington, MB (1)
PMID 30957581, PMID 36774994, PMID 37314061, PMID 20008710, PMID 20427088, PMID 21571677, PMID 22965590, PMID 22999634, PMID 23415775, PMID 23699977, PMID 23706949, PMID 24768239, PMID 25148789, PMID 25439614, PMID 26050541, PMID 26452713, PMID 26519345, PMID 26581718, PMID 26584450, PMID 26802783, PMID 26985629, PMID 26992841, PMID 27234930, PMID 29752001, PMID 30419298, PMID 31047350, PMID 31047503, PMID 31654188, PMID 31668888, PMID 33206392, PMID 37585454, PMID 39680390, PMID 40634898, PMID 40688490, PMID 21220619, PMID 21459214, PMID 23411886, PMID 23761087, PMID 25074698, PMID 26500107, PMID 26662998, PMID 26828801, PMID 27583380, PMID 27881184, PMID 28100402, PMID 29627188, PMID 29801123, PMID 29803986, PMID 30194931, PMID 30350717
2018 (3), U10EY014229 (2), U10EY014231 (2), U10EY018817 (2), 2005 (1), 2014 (1), 2015 (1), 2016 (1), 2017 (1), R01HL126892 (1), U01HL094338 (1)